Elpiscience Biopharmaceuticals, Inc.

科望医药集团

Clinical-stage biopharmaceutical company developing cancer therapies targeting the tumor microenvironment, with a pipeline of six lead clinical and preclinical immuno-oncology assets including OX40 (ES102) and CD39/TGF-β (ES014), and also pursuing autoimmune disease treatments.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Negative operating cash flow
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Non-recurring gains and losses
• Chapter 18A biotech
• Sanctioned countries and export controls